Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/10—Tetrapeptides
  • C07K5/1002—Tetrapeptides with the first amino acid being neutral
  • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/16—Emollients or protectives, e.g. against radiation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
  • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
  • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
  • C07K14/655—Somatostatins
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/10—Tetrapeptides
  • C07K5/1002—Tetrapeptides with the first amino acid being neutral
  • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
  • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/10—Tetrapeptides
  • C07K5/1019—Tetrapeptides with the first amino acid being basic
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/10—Tetrapeptides
  • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Definitions

• the present invention relates to metallopeptides, metal ion-complexed peptidomimetics, and metallo-constructs, including metallopeptide combinatorial libraries, metal ion-complexed peptidomimetic and peptide-like combinatorial libraries and metallo-construct combinatorial libraries, specific for meianocortin receptors, including methods for the use and making of the same.
• the invention also relates to methods for synthesizing and assembling such libraries, and methods for identification and characterization of library constituents which are capable of binding a meianocortin receptor of interest, or mediating a meianocortin receptor-related biological activity of interest.
• Meianocortin Receptors A family of meianocortin receptor types and subtypes have been identified, including melanocortin-1 receptors (MC1-R) expressed on normal human melanocytes and melanoma cells, melanocortin-2 receptors (MC2-R) for ACTH (adrenocorticotropin) expressed in cells of the adrenal gland, melanocortin-3 and melanocortin-4 receptors (MC3-R and MC4-R) expressed primarily in cells in the hypothalamus, mid-brain and brainstem, and melanocortin-5 receptors (MC5-R), expressed in a wide distribution of peripheral tissues.
• MC1-R melanocortin-1 receptors
• M2-R melanocortin-2 receptors
• ACTH adrenocorticotropin
• MC3-R and MC4-R melanocortin-3 and melanocortin-4 receptors
• MC5-R melanocor
• Multivalent melanotropic peptide and fluorescent macromolecular conjugates new reagents for characterization of melanotropin receptors. Bioconjug Chem 5:591-601 , 1994; Sharma SD, Jiang J, Hadley ME, et al. Melanotropic peptide- conjugated beads for microscopic visualization and characterization of melanoma melanotropin receptors. Proc Natl Acad Sci U S A 93(24):13715-13720, 1996).
• the presence of MC1-R has been demonstrated in human melanoma cells by an antibody to MC1-R (Xia Y, Skoog V, Muceniece R, et al.
• MC1-R is a G protein-coupled, 7-transmembrane receptor expressed in skin-cell melanocytes and shares some degree of homology with related receptors MC2-R, MC3-R, MC4-R and MC5-R. Each of these receptors can bind various peptide analogs that contain a common melanotropic pharmacophore, His-Phe-Arg-Trp, which describes the 6-9 sequence of the alpha- melanocyte stimulating hormone ( ⁇ -MSH).
• ⁇ -MSH alpha- melanocyte stimulating hormone
• ⁇ -MSH analogs Prior to molecular characterization of the MC receptors, ⁇ -MSH analogs were labeled with the radioisotope lndium-111 and used in melanoma imaging studies (Wraight EP, Bard DR, Maughan TS, et al. The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma. Brit J Radiology 65: 112-118, 1992; Bard DR, Knight CG and Page-Thomas DP. A chelating derivative of alpha-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma. Brit J Cancer 62:919-922, 1990; Bard DR, Knight CG, Page-Thomas DP.
• MC4-R is also a G protein-coupled, 7-transmembrane receptor, but is believed to be expressed primarily in the brain.
• Alpha-MSH has been described as a potent anti-inflammatory agent in all major forms of inflammation (Star RA, Rajora N, Huang J, Stock RC, Catania A, and Lipton JM: Evidence of autocrine modulation of macrophage nitric oxide synthase by alpha-melanocyte stimulating hormone. Proc Natl Acad Sci U S A 92:8016-8020, 1995; Getting SJ, and Perretti M: MC3-R as a novel target for antiinflammatory therapy. Drug News and Perspectives 13:19-27, 2000). Implication of both MC1-R and MC3-R receptors in anti-inflammatory processes has been stressed. In particular, the activation of these MC receptors by meianocortin receptor agonists has been reported to inhibit the expression of nitric oxide synthase and subsequent nitric oxide production.
• PCT/US98/03298 iodo group-containing meianocortin receptor-specific linear peptide
• PCT/GB99/01388 MC1 -R specific linear peptides
• PCT/GB99/01195 MC3-R, MC4-R and MC5-R specific cyclic peptides
• PCT/US99/04111 MC1-R specific peptide antagonists for melanoma therapy
• PCT/US99/09216 isoquinoline compounds as meianocortin receptor ligands
• PCT/US99/13252 spiropiperdine derivatives as meianocortin receptor agonists
• 6,054,556 (cyclic lactam peptides as MC1-R, MC3-R, MC4-R and MC5-R antagonists).
• a large number of patents teach various methods of screening and determining meianocortin receptor- specific compounds, as for example International Patent Applications No. PCT/US97/15565, PCT/US98/12098 and PCT/US99/16862 and U.S. Patents No. 5,932,779 and 5,994,087.
• compounds specific for MC1-R are believed to be useful for treatment of melanoma, including use as radiotherapeutic or drug delivery agent, and as diagnostic imaging agents, particularly when labeled with a diagnostic radionuclide.
• Compounds specific for MC3-R, MC4-R or MC5-R are believed to be useful in regulation of energy homeostasis, including use as agents for attenuating food intake and body weight gain, for use in treatment of anorexia, as a weight gain aid, for treatment of obesity, and other treatment of other food intake and metabolism-related purposes.
• Compounds specific for MC3-R and MC4-R, among other meianocortin receptors can be used as agents for treatment of sexual dysfunction, including male erectile dysfunction.
• Compounds specific for MC3-R and MC4-R, among other meianocortin receptors can be used to regulate blood pressure, heart rate and other neurophysiologic parameters.
• Other meianocortin receptor peptides can be used as tanning agents, to increase melanin production, such as peptides that are MCR-1 agonists.
• Compounds specific for MCR-1 and MCR-3 may be useful in regulation of inflammatory processes.
• ligands with high specificity for discrete meianocortin receptors as well as ligands or compounds that are either agonists or antagonists of specific meianocortin receptors.
• High affinity peptide ligands of meianocortin receptors can be used to exploit varied physiological responses associated with the meianocortin receptors, either as agonists or antagonists.
• meianocortin receptors have an effect on the activity of various cytokines, and high affinity peptide ligands of meianocortin receptors can be used to regulate cytokine activity.
• the resin is mixed, processed for the next coupling, and again split into equal portions for separate reaction with individual reagents. The process is repeated as required to obtain a library of desired oligomeric length and size.
• This approach is the basis of the "one-bead one-peptide" strategy which employs amino acid sequencing to ascertain the primary structure of the peptide on a hit bead in a bioassay. Automated systems have been developed for carrying out split synthesis of these libraries with rather more efficiency. A common artifact occasionally seen with all these resin bound libraries is altered target-specific affinity by some solid phase bound compounds in bioassays, which can result in totally misleading results.
• Another strategy involves construction of soluble libraries. This strategy involves a deconvolution process of iterative re-synthesis and bioassaying until all the initially randomized amino acid positions are defined.
• soluble libraries This strategy involves a deconvolution process of iterative re-synthesis and bioassaying until all the initially randomized amino acid positions are defined.
• modifications to this strategy have been developed, including co-synthesis of two libraries containing orthogonal pools, which eliminates the need of iterative re-synthesis and evaluation.
• a major limitation of the soluble library approach is its applicability to high affinity systems. The abundance of each compound in solution can be influenced by the total number of compounds in a library that can affect the biological activity. For this reason, a highly active compound in any pool may not in fact be the most potent molecule. Lack of reasonable solubilities of certain members in a library may further influence this phenomenon.
• peptide libraries remain the most versatile because of the structural diversity offered by the use of naturally occurring amino acids, incorporation of a variety of "designer” amino acids, and the high efficiency and ease with which peptide synthesis can be accomplished.
• Another level of structural diversity in peptide-based libraries has been added by post-synthesis modification of the libraries. These modifications include permethylation, acylation, functionalization of the side chain functionality, and reductive amination of the N-terminus.
• the invention provides a construct comprising a metal ion-binding domain comprising two or more linked residues forming an N 3 S ! ligand available for complexing with a metal ion, wherein the construct is conformationally constrained in a structure specific for one or more meianocortin receptors upon complexing the metal ion-binding domain with a metal ion.
• the invention provides a manufactured peptide and pharmaceutically acceptable salts thereof comprising a metal ion-binding domain comprising two or more contiguous amino acids and a determined biological-function domain specific for one or more meianocortin receptors, wherein at least a portion of said biological-function domain is co-extensive with at least a portion of the metal ion-binding domain, and wherein said biological-function domain is conformationally constrained upon complexing the metal ion-binding domain with a metal ion.
• the invention provides a combinatorial library targeted to meianocortin receptors of different sequence peptide members synthesized on solid phase, where each constituent library member comprises:
• a peptide sequence of three or more amino acid residues bound to solid phase characterized by (i) a sequence of two or more amino acid residues forming a metal ion-binding domain and including at least one amino acid residue containing at least one S wherein the said S is protected by an orthogonal S-protecting group, (ii) a sequence of one or more amino acid residues at the N- or C- terminus of the metal ion-binding domain, or at both the N- and C-terminus of the metal ion-binding domain, and (iii) a cleavable bond attaching the peptide sequence to solid phase; and
• the invention provides a combinatorial library targeted to meianocortin receptors of different sequence peptidomimetic members synthesized on solid phase, where each constituent library member comprises:
• a peptidomimetic sequence of a combination of three or more amino acid residues and mimics of amino acid residues bound to solid phase characterized by (i) a sequence of two or more amino acid residues, mimics of amino acid residues or combinations thereof forming a metal ion-binding domain and including at least one amino acid residue or mimic of an amino acid residue containing at least one S wherein the said S is protected by an orthogonal S-protecting group, (ii) a sequence of one or more amino acid residues, mimics of amino acid residues or combinations thereof at the N- or C- terminus of the metal ion-binding domain, or at both the N- and C-terminus of the metal ion-binding domain, and (iii) a cleavable bond attaching the peptidomimetic sequence to solid phase; and
• the invention provides a combinatorial library targeted to meianocortin receptors of different sequence peptide or peptidomimetic members synthesized in solution, where each constituent library member comprises: (a) a peptidomimetic sequence of a combination of three or more amino acid residues and mimics of amino acid residues bound to solid phase characterized by (i) a sequence of two or more amino acid residues, mimics of amino acid residues or combinations thereof forming a metal ion-binding domain and including at least one amino acid residue or mimic of an amino acid residue containing at least one S wherein the said S is protected by an orthogonal S-protecting group, (ii) a sequence of one or more amino acid residues, mimics of amino acid residues or combinations thereof at the N- or C- terminus of the metal ion-binding domain, or at both the N- and C-terminus of the metal ion-binding domain; and
• compositions of this invention include compositions of the formulas:
• Ri is any functionality that potentiates the intrinsic activity of the remainder of the molecule, including but not limited to providing an auxiliary or secondary receptor contact. Any of a variety of amino acids and non-peptide groups may be employed, including an amino acid chain from one to about four neutral or charged L- or D-configuration amino acid residues. If R-, is a non-peptide group, it may be a linear or branched alkyl, aryl, alkene, alkenyl or aralkyl chain;
• Aaa is an L- or D-configuration cationic amino acid with a positively charged side chain.
• Preferred amino acids include L-configuration Lys, Arg, Orn, Dpr or Dbu, and derivatives, analogs or homologs thereof, including both natural and synthetic amino acids.
• Aaa provides an N (nitrogen atom) for metal ion complexation;
• Bbb is an L- or D-configuration amino acid with an aromatic side chain.
• Preferred amino acids include D-configuration Phe, Phe(4'CI), Phe(3',4' Di-CI), Phe(4'-nitro), Phe(4'-methyl), Phe(4'-Phenyl), Hphe, Pgl, Trp, 1-Nal, 2-Nal, Ser(Bzl), Lys(Z), Lys(Z-2'Br), Lys(Bz), Thr(Bzl), Cys(Bzl), or
• Bbb may be functionalized with halogen, alkyl or aryl groups.
• Bbb provides an N for metal ion complexation
• Ccc is an amino acid that provides both an N, from the alpha amino group, and an S (sulfur atom), from a side chain group, for metal ion complexation.
• Preferred amino acids include L- or D- configuration Cys, Pen and Hcys;
• Lll is a D-configuration ammo acid with an aromatic side chain
• Preferred ammo acids include D- configuration Phe, Phe(4'CI), Phe(3',4' Di-CI), Phe(4'-n ⁇ tro), Phe(4'-methyl), Phe(4'-Phenyl), Hphe, Pgl, Trp, 1-Nal, 2-Nal, Ser(Bzl), Lys(Z), Lys(Z-2'Br), Lys(Bz), Thr(Bzl), Cys(Bzl), or Tyr(BzlCI 2 ), and derivatives, analogs or homologs thereof
• the aromatic ring in Lll may be functionalized with halogen, alkyl
• R 2 is an ammo acid with an aromatic side chain
• Preferred ammo acids include L- or D-configuration Phe, Trp, Phe(4'CI), Phe(3',4' Di-CI), Phe(4'-n ⁇ tro), Phe(4'-methyl), Phe(4'-Phenyl), Hphe, Pgl, Trp, 1-Nal, 2-Nal, Ser(Bzl), Lys(Z), Lys(Z-2'Br), Lys(Bz), Thr(Bzl), Cys(Bzl) or Tyr(BzlCI 2 ), and derivatives, analogs or homologs thereof, including both natural and synthetic ammo acids
• the ammo acids include L- or D-configuration Phe, Trp, Phe(4'CI), Phe(3',4' Di-CI), Phe(4'-n ⁇ tro), Phe(4'-methyl), Phe(4'-Phenyl), Hphe, Pgl,
• R 2 may also be the corresponding des-carboxyl ammo acid of any of the foregoing Alternatively, R 2 may be eliminated,
• Ddd is an ammo acid that provides an S, from a side chain group, for metal ion complexation
• Preferred ammo acids include L- or D-configuration Cys, Pen and Hcys
• R 3 is an ammo acid with an aromatic side chain that provides an N for metal ion complexation
• Preferred ammo acids include L- or D-configuration Phe, Trp, Phe(4'CI), Phe(3',4' Di-CI), Phe(4'-n ⁇ tro), Phe(4'-methyl), Phe(4'-Phenyl), Hphe, Pgl, Trp, 1-Nal, 2-Nal, Ser(Bzl), Lys(Z), Lys(Z-2'Br), Lys(Bz), Thr(Bzl), Cys(Bzl) or Tyr(BzlCI 2 ), and derivatives, analogs or homologs thereof, including both natural and synthetic ammo acids
• the C-terminus may be free or amidated
• R 4 is a functionality that provides a cationic center
• Preferred ammo acids include L- or D- configuration Lys, Arg, Orn, Dpr or Dbu, and derivatives, analogs or homologs thereof, including both natural and synthetic ammo acids
• the N-termmus of the ammo acid may be functionalized with any of a variety of neutral ammo acid and non-peptide groups, including linear or branched alkyl, aryl, alkene, alkenyl or aralkyl chains,
• Eee is an uncharged L- or D-configuration ammo acid that provides an N for metal ion complexation
• Preferred ammo acids include Gly and L-configuration Ala, Nle, Leu, Val, Phe or Trp, and derivatives, analogs or homologs thereof, including both natural and synthetic ammo acids
• Eee isn an ammo acid with an aliphatic side chain
• Fff is an L- or D-configuration aromatic ammo acid
• Preferred ammo acids include D-configuration Phe, Phe(4'CI), Phe(3',4' Di-CI), Phe(4'-n ⁇ tro), Phe(4'-methyl), Phe(4'-Phenyl), Hphe, Pgl, Trp, 1-Nal, 2-Nal, Ser(Bzl), Lys(Z), Lys(Z-2'Br), Lys(Bz), Thr(Bzl), Cys(Bzl), Tyr(BzlCI
• Ggg is an L- or D-configuration aromatic ammo acid
• Preferred ammo acids include L-configuration Phe, Phe(4'CI), Phe(3',4' Di-CI), Phe(4'-n ⁇ tro), Phe(4'-methyl), Phe(4'-Phenyl), Hphe, Pgl, Trp, 1-Nal, 2-Nal, Ser(Bzl), Lys(Z), Lys(Z-2'Br), Lys(Bz), Thr(Bzl), Cys(Bzl) or Tyr(BzlCI 2 ), and derivatives, analogs or homologs thereof, including both natural and synthetic amino acids.
• the aromatic ring in Ggg may be substituted with halogen, alkyl or aryl groups.
• Ggg provides an N for metal ion complexation;
• R 5 is preferably an amide, substituted amide, ester or carboxylate group.
• R 5 may also be and L- or D- configuration amino acid or amino acid amide, including an aromatic, aliphatic, neutral or charged amino acid;
• Hhh is an L- or D-configuration cationic amino acid with a positively charged side chain.
• Preferred amino acids include L-configuration Lys, Arg, Orn, Dpr or Dbu, and derivatives, analogs or homologs thereof, including both natural and synthetic amino acids.
• Hhh does not provide an N for metal ion complexation;
• Iii is an L- or D-configuration amino acid that provides an N for metal ion complexation.
• Preferred amino acids includes Ala, Gly, Nle, Val. Leu, lie, His, Lys, or Arg, and derivatives, analogs or homologs thereof, including both natural and synthetic amino acids; Jjj is an L- or D-configuration amino acid with an aromatic side chain.
• Preferred amino acids include D- configuration Phe, Phe(4'CI), Phe(3',4' Di-CI), Phe(4'-nitro), Phe(4'-methyl), Phe(4'-Phenyl), Hphe, Pgl, Trp, 1-Nal, 2-Nal, Ser(Bzl), Lys(Z), Lys(Z-2'Br), Lys(Bz), Thr(Bzl), Cys(Bzl), or Tyr(BzlCI 2 ), and derivatives, analogs or homologs thereof.
• the aromatic ring in Jjj may be functionalized with halogens, alkyl or aryl groups. Jjj does not provide an N for metal ion complexation; and
• Kkk is an L- or D-configuration cationic amino acid with a positively charged side chain.
• Preferred amino acids include L-configuration Lys, Arg, Orn, Dpr or Dbu, and derivatives, analogs or homologs thereof, including both natural and synthetic amino acids.
• Aaa does not provide an N for metal ion complexation.
• the metal ion-binding domain can be complexed with a metal ion, and such compositions are included within the invention.
• the invention further includes compositions wherein the composition is substantially more specific for one or more meianocortin receptors when the metal ion-binding domain is complexed with a metal ion than is the composition when the metal ion-binding amino acid sequence is not complexed with a metal ion.
• the combinatorial libraries of this invention include libraries wherein the metal ion-binding domain further comprises at least one N available for binding to a metal ion upon removal of the orthogonal S-protecting group.
• the combinatorial libraries include compositions wherein the metal ion- binding domain comprises three residues forming an N ⁇ ligand.
• the orthogonal S-protecting group is S-thio-butyl, acetamidomethyl, 4-methoxytrityl, S-sulfonate or 3-nitro-2-pyr idinesulfenyl.
• the orthogonal S-protecting group may be removed from constituent library members thereof without otherwise altering the constituent library members or any amino acid side chain protecting group therein.
• structural diversity may occurs in the metal ion-binding domain or outside the metal ion-binding domain.
• one or more constituent library members may include at least one amino acid residue or mimic of an amino acid residue in the sequence at the N- or C-terminus of the metal ion-binding domain containing at least one S wherein the said S is protected by a non-orthogonal S-protecting group, whereby the orthogonal S-protecting group may be removed without removing the non-orthogonal S-protecting group.
• the amino acid residue containing at least one S wherein the said S is protected by an orthogonal S-protecting group can be an L- or D-3-mercapto amino acid, including but not limited to L- or D-cysteine or L- or D-penicillamine.
• the residue containing at least one S wherein the said S is protected by an orthogonal S-protecting group can be an L- or D-3- mercapto amino acid, including but not limited to L- or D-cysteine or L- or D-penicillamine; 3-mercapto phenylananine; 2-mercaptoacetic acid; 3-mercaptopropionic acid; 2-mercaptopropionic acid; 3- mercapto-3, 3, -dimethyl propionic acid; 3-mercapto-3,3,-diethyl proprionic acid; 3-mercapto,3-methyl propionic acid; 2-mercapto,2-methyl acetic acid; 3-cyclopentamethlene, 3-mercaptopropionic acid; or 2- cyclopentamethlene,2-mercaptoacetic acid.
• L- or D-3- mercapto amino acid including but not limited to L- or D-cysteine or L- or D-penicillamine
• 3-mercapto phenylananine 2-mercapto
• Another object of this invention is to provide peptide-metal ion complexes specific for meianocortin receptors and which have a higher level of stability and are less susceptible to proteolysis than either the uncomplexed peptide, or other peptides known in the art.
• Another object of this invention is to provide peptide-metal ion complexes that are specific for different subsets of meianocortin receptors, such as specific only for MC1-R or for MC4-R.
• Another object of this invention is to provide peptide-metal ion complexes which are specific for meianocortin receptors and which are agonists or antagonists.
• Another object of this invention is to provide for peptide analogs which are not conformationally restricted in the absence of a metal ion, whereby the uncomplexed peptide analog is either inactive or demonstrates low potency, but which is conformationally restricted on complexation with a metal ion and specific for meianocortin receptors with high potency.
• Another object of this invention is to utilize metal complexation in a peptide specific for meianocortin receptors to cause specific regional conformational restrictions in the peptide so that the peptide conformation at the metal binding site is conformationally fixed on metal complexation.
• Another object of this invention is to complex a peptide to a metal ion, whereby the resulting metallopeptide is specific for meianocortin receptors, and exhibits a preferred in vivo biodistribution profile, rate and mode of clearance, bioavailability and pharmacokinetics in mammals.
• Another object of this invention is to provide peptide-metal ion complexes specific for meianocortin receptors utilizing stable non-radioactive metal ions, for use in therapeutic treatment of disease, including as an agent to modify energy metabolism and feeding behavior, such as for treatment of pathologic obesity and related conditions.
• Another object of this invention is to provide peptide-metal ion complexes specific for meianocortin receptors utilizing metal ions which are radionuclides for use in diagnostic methods, including imaging and staging of melanoma tumors and melanoma tumor metastases.
• Another object of this invention is to provide peptide-metal ion complexes specific for meianocortin receptors utilizing stable non-radioactive metal ions, for use as a prevention agent against ultra-violet radiation-induced DNA damages, including sunlight-induced DNA damage in the skin.
• Another object of this invention is to provide peptide-metal ion complexes specific for meianocortin receptors utilizing stable non-radioactive metal ions, for use as a tanning agent, including but not limited to therapeutic use as a tanning agent.
• Another object of this invention is to provide peptide-metal ion complexes specific for meianocortin receptors utilizing stable non-radioactive metal ions, for use as anti-inflammatory agents.
• Another object of this invention is to complex peptides with radiometal ions, including but not limted to technetium-99m, for use in diagnostic imaging, so that the resulting peptide-metal ion complex is substantially more specific for meianocortin receptors than the uncomplexed peptide molecule, and the resulting radiolabeled species is essentially carrier-free in terms of specificity for meianocortin receptors.
• Another object of this invention is to complex peptides with radiometal ions, including radioisotopes of rhenium such as rhenium-186 and rhenium-188, for use in targeted radiotherapy, such as for treatment of melanoma.
• Another object of this invention is to provide peptide-metal ion complexes specific for meianocortin receptors that can transit the gut-blood barrier, without significant enzymatic or peptidase degradation, and may be adapted for oral administration.
• Another object of this invention is to provide libraries of conformationally constrained peptide- metal ion complexes directed to meianocortin receptors.
• Another object of this invention is to provide combinatorial peptide libraries of peptide-metal ion complexes specific for meianocortin receptors, wherein the peptides include a metal ion-binding domain, such that a specific conformational restriction is obtained upon labeling the peptides with a metal ion.
• Another object of this invention is to provide combinatorial peptide libraries of peptide-metal ion complexes specific for meianocortin receptors, wherein the amino acids comprising the peptides may be naturally occurring amino acids, isomers and modifications of such amino acids, non-protein amino acids, post-translationally modified amino acids, enzymatically modified amino acids, constructs or structures designed to mimic amino acids, and the like, so that the library includes pseudopeptides and peptidomimetics.
• Another object of this invention is to provide metallopeptide libraries specific for one or more meianocortin receptors, wherein the metallopeptides include a metal ion-binding domain, such that a determined conformational restriction is obtained upon labeling the peptides with a metal ion, and the metallopeptides further include distinct, unique and different amino acid sequences.
• Another object of this invention is to provide both soluble and solid phase metallopeptide libraries specific for one or more meianocortin receptors, wherein the metallopeptides include a metal ion-binding domain.
• Another object of this invention is to provide methods for synthesis of peptides specific for meianocortin receptors wherein the peptide contains a reactive SH group forming a part of a metal ion- binding domain, whereby the reactive SH group is protected during synthesis, and is deprotected only upon complexing the peptides with a metal ion.
• Another object of this invention is to provide combinatorial metallopeptide libraries specific for meianocortin receptors wherein the peptides forming the library contain a reverse turn structure as a consequence of metal ion complexation.
• Another object of this invention is to provide a method for rapid and efficient complexation of a pool of diverse peptides specific for meianocortin receptors with a metal ion, including a rhenium metal ion.
• Another object of this invention to provide libraries of conformationally constrained peptide-metal ion complexes as surrogates for reverse turn structures, such as beta turns and gamma turns commonly found in naturally occurring peptides and proteins specific for meianocortin receptors.
• the turns formed as a consequence of metal ion complexation are more stable than the naturally occurring turn structures, which are stabilized only by weaker interactions such as van der Waals' interactions and hydrogen bonds.
• Another object of this invention is to provide combinatorial metallopeptide libraries wherein each of the peptides forming the library contain a reverse turn structure as a consequence of metal ion complexation.
• Another object of this invention is to provide a method for the identification of specific metallopeptides through internal signatures resulting from use of metal ions with two or more isotopic peaks, such as through use of rhenium containing two isotopes in fixed relative abundance that differ in mass by 2 units.
• Fig. 1 is a molecular structure for Template 1.
• Fig. 2 is a molecular structure for Template 2.
• Fig. 3 is a molecular structure for Template 3.
• Fig. 4 is a molecular structure for Template 4.
• Fig. 5 is a molecular structure for Template 5.
• Fig. 6 is a molecular structure for Template 6.
• Fig. 7 is a molecular structure for Template 7.
• Fig. 8 is a flow chart of a split pool and combination synthesis method according to Example 2.
• Fig. 9 is a mass spectrum of a library pool of 25 metallopeptides synthesized according to Example 2.
• Fig. 10 is a mass spectrum of a library pool of 4 metallopeptides synthesized according to Example 6.
• Figs. 11 A - 11 E are reversed phased HPLC profiles of a library pool of 4 metallopeptides synthesized according to Example 6.
• binding binding
• complexing complexing
• the "peptides" of this invention can be a) naturally-occurring, b) produced by chemical synthesis, c) produced by recombinant DNA technology, d) produced by biochemical or enzymatic fragmentation of larger molecules, e) produced by methods resulting from a combination of methods a through d listed above, or f) produced by any other means for producing peptides
• peptide as used throughout the specification and claims is intended to include any structure comprised of two or more ammo acids, including chemical modifications and derivatives of ammo acids
• the peptides of this invention comprise fewer than 100 ammo acids, and preferably fewer than 60 ammo acids, and most preferably ranging from about 2 to 20 ammo acids
• the ammo acids forming all or a part of a peptide may be naturally occurring ammo acids, stereoisomers and modifications of such ammo acids, non-protein am o acids, post-translationally modified ammo acids, enzymatically modified am o acids, constructs or structures designed to mimic ammo acids, and the like, so that the term “peptide” includes pseudopeptides and peptidomimetics, including structures which have a non-peptidic backbone
• the term “peptide” also includes dimers or multimers of peptides
• a "manufactured" peptide includes a peptide produced by chemical synthesis, recomb
• am o acid used in this invention, and the term as used in the specification and claims, include the known naturally occurring protein am o acids, which are referred to by both their common three letter abbreviation and single letter abbreviation See generally Synthetic Peptides A User's Guide, GA Grant, editor, W H Freeman & Co , New York, 1992, the teachings of which are incorporated herein by reference, including the text and table set forth at pages 11 through 24
• am o acid also includes stereoisomers and modifications of naturally occurring protein ammo acids, non-protein am o acids, post-translationally modified ammo acids, enzymatically synthesized ammo acids, de ⁇ vatized ammo acids, constructs or structures designed to mimic amino acids, and the like Modified and unusual ammo acids are described generally in Synthetic Peptides A User's Guide, cited above, Hruby VJ, Al-obeidi F and Kazmierski W Biochem J 268 249-262, 1990
• a single ammo acid including stereoisomers and modifications of naturally occurring protein amino acids, non-protein ammo acids, post-translationally modified ammo acids, enzymatically synthesized ammo acids, de ⁇ vatized ammo acids, constructs or structures designed to mimic am o acids, and the like, including all of the foregoing, is sometimes referred to herein as a "residue"
• the library constructs of this invention also include a metal ion, which may be an ionic form of any element in metallic form, including but not limited to metals and metalloids
• the metal ion may, but need not, be radioactive, paramagnetic or superparamagnetic
• the metal ion can be of any oxidation state of any metal, including oxidation states of vanadium (V), manganese (Mn), iron (Fe), cobalt (Co), nickel (Ni), copper (Cu), zinc (Zn), gallium (Ga), arsenic (As), selenium (Se), yttrium (Y), molybdenum (Mo), technetium (Tc), ruthenium (Ru), rhodium (Rh), palladium (Pd), silver (Ag), cadmium (Cd), indium (In), tin (Sn), tungsten (W), rhenium (Re), osmium (Os), iridium (Ir
• the metal ion can also be a radionuclide of any of the foregoing, including In, Au, Ag, Hg, Tc, Re, Sn, At, Y and Cu.
• a preferred metal ion with a tetradentate coordination sphere is Re.
• an alpha-, gamma- or beta-emitting radionuclide may be employed.
• the coordination sphere of various common metal ions in general, is tetradentate to hexadentate.
• an amino acid or amino acid mimetic sequence is included within each library member such that it contains the desired number of groups (4 to 6 in most cases) for complexing with the metal.
• the molecule is designed so that, upon complexing with a metal, it forms a mimic of a reverse turn structure about the site of metal complexation.
• a metal with coordination number 4, 5 or 6, and complexing respectively with an amino acid sequence forming a tetra, penta, or hexadentate ligand, will fold and constrain the ligand.
• the amino acid or amino acid mimetic sequence forming a ligand is defined as the metal ion-binding domain ("MBD") of the peptide or peptidomimetic.
• MBD metal ion-binding domain
• a highly flexible molecule like a peptide in other words, is folded to form a kind of reverse turn upon its complexation with a metal. This resulting turn is a highly constrained structure in the conformational sense.
• the biological-binding domain ("BBD") of the peptide or peptidomimetic is defined in the specification and claims as a sequence of one or more amino acids which constitute a biologically active sequence, exhibiting binding to a melanocotin-associated receptor, including MC1-R, MC2-R, MC3-R, MC4-R and MC5-R, thereby constituting the peptide as a member of a specific binding pair.
• the BBD also includes any sequence, which may be consecutive amino acids or mimetics (sychnological) or non- consecutive amino acids or mimetics (rhegnylogical) which forms a melanocortin-associated ligand, which ligand is capable of forming a specific interaction with its acceptor or receptor.
• the term "receptor" is intended to include both acceptors and receptors.
• the receptor may be a biological receptor.
• the sequence or BBD may transmit a signal to the cells, tissues or other materials associated with the biological receptor after binding, but such is not required.
• the BBD may be either an agonist or antagonist, or a mixed agonist-antagonist.
• a peptide or peptidomimetic complexed to a metal ion with such a BBD constitutes a member of a "specific binding pair," which specific binding pair is made up of at least two different molecules, where one molecule has an area on the surface or in a cavity which specifically binds to a particular spatial and polar organization of the other molecule.
• the members of a specific binding pair are referred to as ligand and receptor or anti-ligand.
• the BBD is further defined to include the portion of a construct, wherein the construct is a peptidomimetic, peptide-like, or metallo-construct molecule, which upon binding of the construct with a metal ion, is biologically active, exhibiting binding to a meianocortin receptor found on cells, tissues, organs and other biological materials.
• the BBD may, in this instance, be sychnological or rhegnylogical, and generally has the attributes and functions of a BBD of a peptide.
• the BBD may be coextensive with all or a portion of the MBD, so that the same amino acids or other residues which constitute the MBD also constitute all or a part of the BBD. In some instances, one or amino acids of the MBD will form a part of the BBD, and one or more additional amino acids, which are not part of the MBD, form the remainder of the BBD.
• Conformationai constraint refers to the stability and preferred conformation of the three- dimensional shape assumed by a peptide or other construct.
• Conformationai constraints include local constraints, involving restricting the conformationai mobility of a single residue in a peptide; regional constraints, involving restricting the conformationai mobility of a group of residues, which residues may form some secondary structural unit; and global constraints, involving the entire peptide structure. See generally Synthetic Peptides: A User's Guide, cited above.
• the primary structure of a peptide is its amino acid sequence.
• the secondary structure deals with the conformation of the peptide backbone and the folding up of the segments of the peptide into regular structures such as ⁇ -helices, ⁇ -sheets, turns and the like.
• the three-dimensional shape assumed by a peptide is directly related to its secondary structure. See generally Synthetic Peptides: A User's Guide, cited above, including the text, figures and tables set forth at pages 24-33, 39-41 and 58-67.
• a global structure refers to a peptide structure which exhibits a preference for adopting a conformationally constrained three-dimensional shape.
• the product resulting from the methods set forth herein can be used for both medical applications and animal husbandry or veterinary applications. Typically, the product is used in humans, but may also be used in other mammals.
• the term "patient” is intended to denote a mammalian individual, and is so used throughout the specification and in the claims.
• the primary applications of this invention involve human patients, but this invention may be applied to laboratory, farm, zoo, wildlife, pet, sport or other animals.
• the products of this invention may optionally employ radionuclide ions, which may be used for diagnostic imaging purposes or for radiotherapeutic purposes.
• Libraries of this invention contain constituents which are either locally or globally constrained structures. Libraries may include molecules with either local conformation restrictions or global conformation restrictions, or some combination thereof.
• This aspect of the invention includes a variety of methods of synthesis, screening and structural elucidation of positive hits in screening systems. The importance of these aspects is well known to those skilled in the art and will also become evident from the following description and examples.
• Coordinating groups in the peptide chain include nitrogen atoms of amme, amide, imidazole, or guanidmo functionalities, sulfur atoms of thiols or disulfides, and oxygen atoms of hydroxy, phenolic, carbonyl, or carboxyl functionalities
• the peptide chain or individual ammo acids can be chemically altered to include a coordinating group, such as oxime, hydrazmo, sulfhydryl, phosphate, cyano, py ⁇ dino, pipe ⁇ dino, or morphohno groups
• a tetrapeptide ammo acid sequence may be employed (such as G
• a free thiol (SH) group is preferred for complexation of most metal ions to the peptides and peptidomimetics of this invention, and in many cases an SH group is necessary in order to form a stable exchange-inert complex with a metal Peptides and other organic molecules with free SH groups, however, are easily oxidized in air and in solution, and can often form a disulfide-linked dimer If more than one free SH group is present in a molecule, oxidation may lead to a complex polymer Similarly, if a mixture of different peptides or organic molecules with free SH groups are prepared, oxidation generally leads to a complex mixture of polymers of unknown composition This is of serious concern in preparing libraries of metallopeptides or other organic molecules where one or more SH group is intended for use in metal complexation
• SH protecting groups have been employed for a variety of purposes, including radiopharmaceutical manufacture and formulation
• S-Benzoyl- mercaptoacetyl-glycyl-glycyl-glycme Bz-MAG 3
• Tc-99m 99m Tc
• S-Bz protection is not compatible with the methods of peptide synthesis
• metallopeptide libraries of this invention which incorporate an SH group
• the peptides must be S-protected derivatives
• the SH protecting group is chosen such that (a) the synthesis of peptide derivatives with S-protecting group is compatible with methods of solution and solid phase peptide synthesis, so that the S-protecting group is stable during synthetic procedures, and (b) the S-protecting group can be deprotected in situ, without cleavage from the resin in the case of solid phase synthesis, during the metal complexation step
• Many prior art methods, such as Bz-MAG 3 meet at most only one of the two criteria specified above (Bz-MAG 3 meets only criterion (a) above)
• orthogonally S-protected thiol groups permits synthesis of metallo-compounds in a single pot
• a mixture of compounds, each compound containing an orthogonal S-protected group (“OSPG"), is used for complexation with a metal ion, and it is only during metal ion complexation that the S-protected group is deprotected, and accordingly polymerization and cross-linking is avoided
• OSPG orthogonal S-protected group
• S 4 Bu group is stable under both the acidic and basic conditions typically employed in peptide synthesis
• the S ( Bu group may be cleaved by reduction using a suitable phosphme reagent, which reduction step may be employed immediately prior to or in conjunction with complexation of a metal ion to the peptide
• Such OSPG cleavage does not cleave the peptide from the resin, or otherwise alter the structure of the peptide
• Another OSPG meeting the criteria specified above and suitable for this invention employs an S- Acm (S-acetamidomethyl) group to protect the SH group
• the Acm group is also stable under the acid and base conditions usually employed during peptide synthesis
• the S-Acm group may be removed by treatment of S-Acm-protected peptide or peptide resin with mercury (II) acetate or silver (I) tertrafluoroborate, which liberates the thiol peptide in its mercury or silver ion-complexed state
• Free thiol-containmg peptide can then be recovered by treating the mercury or silver ion and thiol complexed salts with an excess of a thiol-containmg reagent, such as beta-mercaptoethanol or dithiothreitol
• a thiol-containmg reagent such as beta-mercaptoethanol or dithiothreitol
• OSPGs for metallopeptides include 4-methoxytr ⁇ tyl (Mmt), 3-n ⁇ tro-2- py ⁇ dinesulfenyl (Npys) and S-sulfonate (S0 3 H) Mmt is selectively removed upon treatment with 1 % TFA in dichloromethane Npys and S-sulfonate are selectively removed by treatment with a thiol- containmg reagent such as beta-mercaptoethanol or dithiothreitol or a phosphme reagent such as tnbutyl phosphme
• the Npys group (R G Simmonds RG et al Int J Peptide Protein Res, 43 363,1994) is compatible with Boc chemistry for peptide synthesis and the S-sulfonate (Maugras I et al Int J Peptide Protein Res, 45 152, 1995) is compatible with both Fmoc and Boc chemist
• the complexation of metal ions to the sequences in a library, and specifically to the MBD is achieved by mixing the sequences with the metal ion This is conveniently done in solution, with the solution including an appropriate buffer
• the metal ion is, when mixed with the peptide or peptidomimetic constituents, already in the oxidation state most preferred for complexing to the MBD
• Some metal ions are complexed in their most stable oxidation state, such as calcium (II), potassium (I), indium (III), manganese (II), copper (II), zinc (II) and other metals
• the metal must be reduced to a lower oxidation state in order to be complexed to the MBD This is true of ferrous, ferric, stannous, stannic, technet ⁇ umoxo[V], pertechnetate, rhen ⁇ umoxo[V], perrhenate and other similar metal ions Reduction may be performed prior to mixing with the sequences, simultaneously with mixing with
• Solid phase resin bound peptide or peptidomimetic sequences may be labeled with rhenium ion by treatment with the rhenium transfer agent ReOCI 3 (PPh 3 ) 2 in the presence of 1 ,8-Diazabicyclo[5,4,0] undec-7-ene as a base. The sequences may then be cleaved from the resin.
• peptide or peptidomimetic sequences in a soluble library may similarly be labeled by treatment with the rhenium transfer agent ReOCI 3 (PPh 3 ) 2 in the presence of 1 ,8-Diazabicyclo[5,4,0] undec-7-ene as a base.
• Metal complexation in the presence of 1 ,8-Diazabicyclo[5,4,0]undec-7-ene (DBU) as a base can conveniently be accomplished at ambient room temperature.
• a mild base such as sodium acetate
• the thiol-containing sequence either in solution or bound to solid phase, is taken in a suitable solvent, such as DMF, NMP, MeOH, DCM or a mixture thereof, and heated to 60-70°C with the rhenium transfer agent ReOCI 3 (PPh 3 ) 2 in the presence of sodium acetate for 15 minutes.
• a suitable solvent such as DMF, NMP, MeOH, DCM or a mixture thereof
• ReOCI 3 rhenium transfer agent
• other bases such as triethylamine, ammonium hydroxide and so on, may be employed.
• MeOH is a preferred choice of solvent for rhenium complexation in the case of S- deprotected peptides in solution.
• the solvent choice for S-deprotected peptides still attached to the solid phase is guided mainly by considerations of superior solvation (swelling) of the solid phase.
• DMF and NMP may be employed.
• Various mixtures of these solvents, also in combination with MeOH, and DCM, CHCI 3 and so on, may also be employed to yield optimized complexation results.
• an S*Bu protected peptide is treated in situ with rhenium transfer agent in the presence of DBU and tributylphosphine to effect S-deprotection and rhenium complexation in one pot.
• complexation of rhenium to the S l Bu protected peptide in the presence of rhenium perrhenate may be accomplished by treatment with Sn[ll]CI 2 .
• This reagent effects S-deprotection as well as conversion of Re0 4 state to ReO state in situ to cause complexation of the rhenium to the S-deprotected peptide.
• a preferred procedure in this invention is the use of S l Bu protected peptide with S-deprotection by treatment with tributylphosphine, and metal complexation of the resulting peptide utilizing ReOCI 3 (PPh 3 ) 2 in the presence of DBU at room temperature.
• the MBD forms a reverse turn structure upon complexation with a metal ion, with the library constructed such that side chains of amino acids within the MBD are varied, and similarly amino acids not forming a part of the MBD are also varied.
• Various compounds in a library of metallopeptides can be obtained by varying the sequence of amino acids in a set of peptides that are all optimized to form a complex of nearly similar geometry when coordinated with a metal ion. This optimization can be obtained, for example, by appropriate positioning of amino acids having high affinity to complex a metal ion. Examples of naturally occurring amino acids with high affinity for metal complexation include Cys and His.
• a library of such peptides therefore, would have at least one of these amino acids that is suitably placed in the sequence, with this amino acid being common to all the molecules in the library, with this amino acid thus non-randomized.
• a conceptual, generalized view of a solid phase library of metallopeptides that is constructed using local conformationai restriction is:
• Ai and A 2 are amino acid side chains forming parts of the reverse turn structure which is the BBD, and "Peptide Chain” denotes one or more amino acids.
• a similar library can also be constructed in which the components are soluble, and thus not bound to a resin.
• Another embodiment of this invention provides for construction of a library with global conformationai restriction.
• the MBD can be held constant, and a randomized or selected series of sequences of amino acids or mimetics varied to form the library.
• This type of library encompasses metallopeptides in which a MBD is an isosteric replacement for a disulfide, lactam, lactone, thioether or thioester moiety in cyclic peptides.
• a set MBD is introduced between two pre-selected ends of a linear peptide or peptidomimetic that contains the randomized or selected series of sequences of amino acids or mimetics under investigation.
• the general structure of a metallopeptide library of this type is:
• Peptide Chain (Containing Biological Function Domain)— Resin where M is a metal ion and A, and A 2 are structural elements that may provide additional stability to metal complexation, or may modulate biological activity, such as determining the organ of clearance, or altering biodistribution patterns or pharmacokinetics.
• the "Peptide Chain” sequence may be randomly varied, thereby resulting in a random library, or may be directed in a predetermined fashion, based upon known characteristics of the target molecule.
• One illustration of a globally-constrained metallopeptide library is a library of peptides wherein all the individual members of the library include a metal ion-binding domain and the library is directed specifically towards a family of meianocortin receptors.
• the general formula of this library of peptides, before complexation to a metal ion is: A Aa Aa 2 - Aa 3 -A 2 ⁇ Res/n
• X is a fixed MBD including a plurality of ammo acids, so that all of the valences of the metal ion are satisfied upon complexation of the metal ion with X
• a T and A 2 each comprise from 0 to about 20 ammo acids
• Aa ⁇ Aa 2 and Aa 3 each comprise one or more am o acids connected to X through an amide, thioether, thioester, ester, carbamate, or urethane bond, wherein each of Aa ⁇ Aa 2 and Aa 3 is varied
• the MBD may include an OSPG
• Other thiols in the sequence may optionally include S-protecting groups that are not orthogonal, such that the OSPG may be removed without removal of other S-protecting groups in the sequence
• each these peptide libraries may also be obtained through the development of a library of non-ammo acid building blocks so as to result in structural mimics of these peptides
• the peptide bonds may be replaced by pseudopeptide bonds, such as thioamides, thioethers, substituted amines, carbanate, urethane, aliphatic moieties, and functionally similar constructs
• a peptide library is first assembled according to the sequence specification and degeneration, as described above, by well-known methods of peptide synthesis These libraries can be synthesized as discreet, spatially addressable compounds in parallel synthesis, using split synthesis approaches, or by deconvolution techniques of soluble libraries Using similar methods, a pseudopeptide, peptidomimetic or non-peptide library can be obtained.
• the non-peptide libraries may also optionally incorporate one of various tagging approaches that are well known to those skilled in the art Both solid-phase and soluble libraries can be obtained in this manner
• the entire library is then reacted with an appropriate metal- complexmg agent to obtain the corresponding metal-coordinated library, comprising a similar class of predetermined structures
• the peptide library can be treated with Re(0)CI 3 (PPh 3 ) 2 in the presence of sodium acetate This procedure results in quantitative complexation of ReO with the peptide
• a metallopeptide library constructed according to this invention can be screened to identify one or more receptor-bmdmg or pharmacologically-active meianocortin receptor-specific candidates by various techniques that have been reported in the prior art Both soluble and solid phase libraries may be directly employed in these assays These techniques include direct target binding approaches as described by Lam and coworkers (Lam KS et al: Nature 354:82-84, 1991 , Lam KS et al.
• the deconvolution and iterative resynthesis approach may be directly applied to soluble metallopeptide libraries to elucidate the structure of a "hit," or peptide identified as a receptor-bmdmg or pharmacologically-active candidate in the screening process
• the structure of hits can be directly determined by various strategies well known to those skilled in the art These include direct mass spectromet ⁇ c analysis of compounds covalently bound to solid phase matrix of particles by the use of matrix-assisted laser desorption/ionization (MALDI) techniques (Siuzdak G et al Bioorg Med Chem Lett 6:979, 1996, Brown BB et ai Molecular Diversity 1 -4-12, 1995)
• MALDI matrix-assisted laser desorption/ionization
• molecular templates which may be employed in this invention are shown below for tetradentate metal ion complexation
• these molecular templates define groups of metallopeptides of this invention which, by substitution as provided, give rise to libraries of metallopeptides for use in determining meianocortin receptor-specific compounds, which may be either agonist or antagonist compounds
• the templates are provided without the metal ion, it being understood that the compounds exhibit enhanced specificity for meianocortin receptors only upon metal ion complexation.
• R-i is any functionality that potentiates the intrinsic activity of the remainder of the molecule, including but not limited to providing an auxiliary or secondary receptor contact. Any of a variety of amino acids and non-peptide groups may be employed, including an amino acid chain from one to about four neutral or charged L- or D-configuration amino acid residues. If R, is a non-peptide group, it may be a linear or branched alkyl, aryl, alkene, alkenyi or aralkyl chain.
• Aaa is an L- or D-configuration cationic amino acid with a positively charged side chain.
• Preferred amino acids include L-configuration Lys, Arg, Orn, Dpr or Dbu, and derivatives, analogs or homologs thereof, including both natural and synthetic amino acids.
• Aaa provides an N (nitrogen atom) for metal ion complexation.
• Bbb is an L- or D-configuration amino acid with an aromatic side chain.
• Preferred amino acids include D-configuration Phe, Phe(4'CI), Phe(3',4' Di-CI), Phe(4'-nitro), Phe(4'-methyl), Phe(4'- Phenyl), Hphe, Pgl, Trp, 1-Nal, 2-Nal, Ser(Bzl), Lys(Z), Lys(Z-2'Br), Lys(Bz), Thr(Bzl), Cys(Bzl), or Tyr(BzlCI 2 ), and derivatives, analogs or homologs thereof.
• the aromatic ring in Bbb may be functionalized with halogen, alkyl or aryl groups.
• Bbb provides an N for metal ion complexation.
• Ccc is an amino acid that provides both an N, from the alpha amino group, and an S (sulfur atom), from a side chain group, for metal ion complexation.
• Preferred amino acids include L- or D-configuration Cys, Pen and Hcys.
• Lll is a D-configuration amino acid with an aromatic side chain.
• Preferred amino acids include D-configuration Phe, Phe(4'CI), Phe(3',4' Di-CI), Phe(4'-nitro), Phe(4'-methyl), Phe(4'-Phenyl), Hphe, Pgl, Trp, 1-Nal, 2-Nal, Ser(Bzl), Lys(Z), Lys(Z-2'Br), Lys(Bz), Thr(Bzl), Cys(Bzl), or Tyr(BzlCI 2 ), and derivatives, analogs or homologs thereof.
• the aromatic ring in Lll may be functionalized with halogen, alkyl or aryl groups. Lll does not provide an N for metal ion complexation.
• R 2 is an amino acid with an aromatic side chain.
• Preferred amino acids include L- or D- configuration Phe, Trp, Phe(4'CI), Phe(3',4' Di-CI), Phe(4'-nitro), Phe(4'-methyl), Phe(4'-Phenyl), Hphe, Pgl, Trp, 1-Nal, 2-Nal, Ser(Bzl), Lys(Z), Lys(Z-2'Br), Lys(Bz), Thr(Bzl), Cys(Bzl) or Tyr(BzlCI 2 ), and derivatives, analogs or homologs thereof, including both natural and synthetic amino acids.
• the C- terminus may be free or amidated.
• R 2 may also be the corresponding des-carboxyl amino acid of any of the foregoing. Alternatively, R 2 may be eliminated.
• Fig. 1 depicts the structure of Template 1
• Fig. 2 depicts the structure of Template 2, in both cases showing coordination with a tetradenate coordination sphere metal ion, resulting in an N 3 S- ⁇ metal ion bond.
• Ddd is an amino acid that provides an S, from a side chain group, for metal ion complexation.
• Preferred amino acids include L- or D-configuration Cys, Pen and Hcys.
• R 3 is an amino acid with an aromatic side chain that provides an N for metal ion complexation.
• Preferred amino acids include L- or D-configuration Phe, Trp, Phe(4'CI), Phe(3',4' Di-CI), Phe(4'-nitro), Phe(4'-methyl), Phe(4'-Phenyl), Hphe, Pgl, Trp, 1-Nal, 2-Nal, Ser(Bzl), Lys(Z), Lys(Z-2'Br), Lys(Bz), Thr(Bzl), Cys(Bzl) or Tyr(BzlCI 2 ), and derivatives, analogs or homologs thereof, including both natural and synthetic amino acids.
• the C-terminus may be free or amidated.
• R 3 may also be the corresponding des-carboxyl amino acid of any of the foregoing.
• Fig. 3 depicts the structure of Template 3, showing coordination with a tetradenate coordination sphere metal ion, resulting in an N 3 S-
• R 2 , Bbb and Ccc are as described above.
• R 4 is a functionality that provides a cationic center.
• Preferred amino acids include L- or D- configuration Lys, Arg, Orn, Dpr or Dbu, and derivatives, analogs or homologs thereof, including both natural and synthetic amino acids.
• the N-terminus of the amino acid may be functionalized with any of a variety of neutral amino acid and non-peptide groups, including linear or branched alkyl, aryl, alkene, alkenyl or aralkyl chains.
• Eee is an uncharged L- or D-configuration amino acid that provides an N for metal ion complexation.
• Preferred amino acids include Gly and L-configuration Ala, Nle, Leu, Val, Phe or Trp, and derivatives, analogs or homologs thereof, including both natural and synthetic amino acids.
• Eee isn an amino acid with an aliphatic side chain.
• Fig. 4 depicts the structure of Template 4, showing coordination with a tetradenate coordination sphere metal ion, resulting in an N ⁇ metal ion bond.
• Fff is an L- or D-configuration aromatic amino acid.
• Preferred amino acids include D- configuration Phe, Phe(4'CI), Phe(3',4' Di-CI), Phe(4'-nitro), Phe(4'-methyl), Phe(4'-Phenyl), Hphe, Pgl, Trp, 1-Nal, 2-Nal, Ser(Bzl), Lys(Z), Lys(Z-2'Br), Lys(Bz), Thr(Bzl), Cys(Bzl), Tyr(BzlCI 2 ), Tic, Tiq or Tea, and derivatives, analogs or homologs thereof, including both natural and synthetic amino acids.
• the aromatic ring in Fff may be substituted with halogen, alkyl or aryl groups. Fff does not provide an N for metal ion complexation.
• Ggg is an L- or D-configuration aromatic amino acid.
• Preferred amino acids include L- configuration Phe, Phe(4'CI), Phe(3',4' Di-CI), Phe(4'-nitro), Phe(4'-methyl), Phe(4'-Phenyl), Hphe, Pgl, Trp, 1-Nal, 2-Nal, Ser(Bzl), Lys(Z), Lys(Z-2'Br), Lys(Bz), Thr(Bzl), Cys(Bzl) or Tyr(BzlCI 2 ), and derivatives, analogs or homologs thereof, including both natural and synthetic amino acids.
• the aromatic ring in Ggg may be substituted with halogen, alkyl or aryl groups.
• Ggg provides an N for metal lon complexation
• R 5 is preferably an amide, substituted amide, ester or carboxylate group
• R 5 may also be and L- or D-configuration ammo acid or ammo acid amide, including an aromatic, aliphatic, neutral or charged ammo acid
• Fig. 5 depicts the structure of Template 5, showing coordination with a tetradenate coordination sphere metal ion, resulting in an N 3 Si metal ion bond
• Hhh is an L- or D-configuration cationic am o acid with a positively charged side chain
• Preferred ammo acids include L-configuration Lys, Arg, Orn, Dpr or Dbu, and derivatives, analogs or homologs thereof, including both natural and synthetic ammo acids Hhh does not provide an N for metal ion complexation
• Fig. 6 depicts the structure of Template 6, showing coordination with a tetradenate coordination sphere metal ion, resulting in an N ⁇ metal ion bond Ri - iii - Iii - Ccc - Jjj - Kkk - R 2 Template 7
• Preferred ammo acids includes Ala, Gly, Nle, Val Leu, lie, His, Lys, or Arg, and derivatives, analogs or homologs thereof, including both natural and synthetic ammo acids
• JJJ is an L- or D-configuration ammo acid with an aromatic side chain
• Preferred am o acids include D-configuration Phe, Phe(4'CI), Phe(3',4' Di-CI), Phe(4'-n ⁇ tro), Phe(4'-methyl), Phe(4'- Phenyl), Hphe, Pgl, Trp, 1-Nal, 2-Nal, Ser(Bzl), Lys(Z), Lys(Z-2'Br), Lys(Bz), Thr(Bzl), Cys(Bzl), or Tyr(BzlCI 2 ), and derivatives, analogs or homologs thereof
• the aromatic ring in JJJ may be functional
• Preferred ammo acids include L-configuration Lys, Arg, Orn, Dpr or Dbu, and derivatives, analogs or homologs thereof, including both natural and synthetic am o acids Aaa does not provide an N for metal ion complexation
• Fig. 7 depicts the structure of Template 7, showing coordination with a tetradenate coordination sphere metal ion, resulting in an N 3 S ⁇ metal ion bond
• the foregoing templates may be employed with tetradentate coordination sphere metal ions, such as various forms of technetium and rhenium
• Corresponding templates may be constructed for use with metal ions of other coordination spheres
• Representative Peptides of this Invention Representative peptides of this invention were made using library and synthesis methods described herein, and selected peptides were tested using a Where Kkk is an L- or D-configuration cationic ammo acid with a positively charged side chain Preferred ammo acids include L-configuration Lys, Arg, Orn, Dpr or Dbu, and derivatives, analogs or homologs thereof, including both natural and synthetic ammo acids Aaa does not provide an N for metal ion complexation
• Fig. 7 depicts the structure of Template 7, showing coordination with a tetradenate coordination sphere metal ion, resulting in an N 3 Si metal ion bond
• the foregoing templates may be employed with tetradentate coordination sphere metal ions, such as various forms of technetium and rhenium
• Corresponding templates may be constructed for use with metal ions of other coordination spheres
• Representative Peptides of this Invention Representative peptides of this invention were made using library and synthesis methods described herein, and selected peptides were tested using a binding assay Table 1 sets forth peptides of this invention, and the results of competitive inhibition binding assays The peptides were synthesized using conventional peptide synthesis methods, and were complexed with rhenium using the methods described herein The competitive inhibition binding assay was conducted using membranes prepared from hMC4-R and B-16 mouse melanoma cells (containing MC1-R) using 0 4 nM 125 l-NDP-alpha-MSH (New England Nuclear, Boston, MA, USA) in 50 mM HEPES buffer containing 1 mM MgCI 2 , 2 mM CaCI 2 ,
• a cAMP assay was also performed Human MC4-R or B-16 cells were grown to confluence in 96 well plates (plating approximately 250,000 cells per well) Identical sets of cells in triplicate were treated with 0 2 mM isobutylmethylxanthine (IBMX) and the chosen concentration of the rhenium metal ion-complexed peptide and the rhenium metal ion- complexed peptide in the presence of 20 nM alpha-MSH Cells similarly treated but with only 20 nM alpha-MSH served as positive control A buffer blank, as a negative control, was also included Incubation was for one hour at 37°C after which the medium was aspirated and the cells extarted with 150 microliters of HCI Total cAMP accumulated in 100 microliters of this solution was quantitated using a commercially available low pH cAMP assay kit (R&D Systems) by the procedure specified by the kit supplier The table shows the amount of
• metallopeptides of this invention that are MC1-R specific can be used, when complexed to 99 Tc as a radiodiagnostic agent, for imaging melanoma tumor metastases, and when complexed to rhenium-188 ( 188 Re), rhenium-186 ( 186 Re) or other therapeutic radionuclides as a radiotherapeutic agent for treatment of melanoma tumors and metastatic tumors.
• melanoma has a complex antigenic profile. It is generally believed that malignant melanoma is derived by UV activity from DOPA positive melanocytes, the melanin (skin pigment) producing units. Primary diagnosis involves electron microscopic examination to reveal the presence or absence of pre-melanosomes. Melanotic melanoma is classified as dendritic, spindle, playful, large epitheloid, small nevus and so on. Amelanotic melanoma, on the other hand, is frequently misdiagnosed because the histology of these cells resembles that of malignant iymphoma, carcinoma or sarcoma. Therefore, morphological evaluation may not prove reliable for clinical diagnosis.
• the product can be formulated as a single-vial, lyophilized radiolabehng kit containing the peptide in an uncomplexed state, buffer, and a reducing agent for pertechnetate To induce radiolabehng, resulting in a metallopeptide, the vial is incubated after the addition of sodium pertechnetate
• a 5-10 ⁇ g sample of the peptide taken in 0 001 N aq HCI is mixed with 1-30 mCi of generator-eluted Na 99m Tc0 4 in a 5 ml serum vial
• the volume of the resulting mixture is adjusted to 600 ⁇ l using mjectable saline
• a 400 ⁇ l volume of freshly prepared and nitrogen-purged phthalate-tartrate-Sn(ll) buffer (40 10 1 mM) is added to the vial under a nitrogen head space
• the vial is immediately sealed and placed in a shielded boiling water bath After 15 minutes the vial is removed from the water bath and allowed to come to room temperature
• the radiochemical purity, as calculated from HPLC profiles, ranges from 90-99%
• the peptides of this invention may alternatively be labeled with 99m Tc by other means, including use of stannous-tartrate-succinate buffer, stannous-EDTA-succmate buffer, stannous stabilized in gluco
• the metallopeptides of this invention may be delivered to a subject by any means known in the art This includes intravenous injection, subcutaneous injection, administration through mucous membranes, oral administration, dermal administration, regional administration to an organ, cavity or region, and the like
• Imaging may be any means known in the art, including gamma camera and SPECT imaging Imaging may commence immediately after administration, and may include time course radiographic studies, and imaging may continue so long as images may be obtained
• the MC1-R specific metallopeptides of this invention may be used as melanoma specific tumor imaging and staging agent These uses include early detection and localization of primary and disseminated lesions, identification of lymph nodes containing lesions, radioimmunoguided surgery applications and the like Tumor imaging using a 99m Tc-labeled metallopeptide of this invention selective for the MC1-R will further help in formulating the optimal clinical treatment modality, whether surgical, radiation or chemotherapeutic
• metallopeptides of this invention that are MC1-R specific can be used as chemoprevention agents against sun-induced, such as by UV radiation, neoplastic activity in human skin MC1-R agonist metallopeptides of this invention may be employed to stimulate epidermal melanocytes to produce melanin as well as to convert pheomelanin to eumelanin Eumelanin, which is dark brown or black pigmentation, is considered more photo- protective than pheomelanin, which is yellow or red pigmentation
• the dark pigment eumelanin a brown/black pigment incorporating dopa-based structural units, is the mam photoprotective agent in skin
• Lighter colored people have higher levels of pheomelanin, a red/yellow pigment having predominantly cysteine and related sulfur-based structural units, which is an inefficient UV absorber
• the process of melanogenesis is believed to involve stimulation of MC1-R in epidermal melanocytes, thereby mediating the stimulation of tyrosmase enzymes within these pigment cells, inducing the conversion of tyrosine to dopa and then through dopaqumone to eumelanin Sun tanning due to direct sun exposure is also proposed to result from the same pathway by local production of melanotropic peptide from a POMC gene in the epidermis
• stimulation of eumelanin production and conversion of pheomelanin to eumelanin may be a desirable chemo
• a potent, high-affinity and highly selective MC1-R agonist metallopeptide of this invention can accordingly be used as a therapeutic chemoprevention agent for combating harmful sun, or UV, exposure that induces neoplastic activity in skin melanocytes
• MC4-R agonists can be used as a therapeutic agent to modify energy metabolism and feeding behavior, including treatment of pathologic obesity and related conditions
• Metallopeptides of this invention that are MC4-R antagonists can also be used as a therapeutic agent in eating disorders, such as treatment of anorexia Control centeis for eating and satiety reside in the hypothalamus These responses are determined by diverse hormones and soluble factors that signal through specific receptors in the hypothalamus MC4-R is known to be expressed in the brain, and mactivation of this receptor by gene targeting has resulted in mice with the maturity-onset obesity syndrome that is associated with hyperphagia, hype ⁇ nsuhnemia and hyperglycemia
• metallopeptides of this invention may used as therapeutic agents for treatment of sexual dysfunction, including treatment of both male erectile dysfunction and female sexual dysfunction
• metallopeptides of this invention may be used as therapeutic agents for treatment of inflammation, including specifically MC1-R and MC3-R agonist
• the library design was based on the tetrapeptide message sequence, His-Phe-Arg-Trp (6-9 sequence), of ⁇ -MSH. This sequence exists as a reverse turn, making it suitable for conversion into a metallopeptide format of this invention.
• metallopeptides were designed around a tripeptide N 3 S ⁇ MBD designed for a rhenium metal ion.
• the MBD was derivatized to yield the pentapeptide Ac-His-Phe-Arg-Cys-Trp-NH 2 as a putative candidate for meianocortin ("MC") receptors.
• the template structure was used to define a small combinatorial library utilizing split synthesis methodologies.
• the final template selected for the combinatorial library was Ac-D-His-Xaa-D-Cys- Trp-NH 2 , where Xaa was D-(2') Naphthylalanine, D-Trp, D-HomoPhe, or D-Phenylglycine.
• the peptide resin, Cys(S'Bu)-Trp(Boc)-Resin was split in four equal parts. Each part was reacted with one of the four Xaa types. After coupling, the resin pools were mixed and synthesis continued in a single pool to couple the His residue. The final result was four separate peptides in a single pool, each peptide varying by one amino acid, in the Xaa position.
• An S l Bu OSPG group was used to protect the SH group during synthesis.
• the S'Bu group was split using tributylphosphine.
• the resulting free SH-containing peptide-resin was treated with the rhenium transfer agent Re(0)CI 3 (PPh 3 ) 2 in the presence of 1 ,8-Diazabicyclo[5,4,0] undec-7-ene as base.
• the resulting metallopeptide resin was then treated with TFA to cleave it from the resin and de-protect all the side chain protecting groups. The products were analyzed by mass spectrometry.
• the library was rationally designed based upon data relating to meianocortin receptors and peptide sequences specific to the meianocortin receptors, including melanotropin side-chain pharmacophores, D-Phe 7 and Trp 9 , that interact with a hydrophobic network of receptor aromatic residues in transmembrane regions 4, 5, 6, and 7. Based on this design criterions, a pharmacophore for the meianocortin receptor was preliminarily defined, and a combinatorial library designed for identification of potent and receptor-selective agonists.
• the putative structure R-Aaa-Baa-L-Cys-Caa-NH 2 was selected, in which each of Aaa, Baa and Caa are selected from L- or D-isomers of 2-Nal (1 ), Phe (2), Trp (3), Tyr (4) and Ala (5), so that any one of the foregoing can be substituted for any one of Aaa, Baa or Caa.
• the five amino acids were designated 1 through 5, with the isomerism conventionally notated, so that, for example, Baa 2 L refers to L-Phe in the Baa position.
• the terminal R group represents a truncated amino acid, and offers additional structural diversity.
• a pool and split library synthesis scheme was employed such that 5,000 separate compounds were synthesized, resulting in 200 final pools each containing 25 different compounds, with the compounds differing solely by the amino acids in the Aaa and Baa position.
• binding characteristics relating to the Caa amino acid or R terminal group can be identified through inter-group comparison, thereby simplifying the deconvolution strategy.
• the library synthesis steps are set forth in Fig. 8.
• the resin of step 1 was divided into 10 groups.
• each of Caa ⁇ through Caa 5 D were coupled to an individual resin group, and L-Cys was coupled to each resin group, resulting in 10 groups and 20 couplings.
• Each of the resin groups of step 2 was then divided into 10 sub-groups as shown at step 3 (with only one subgroup illustrated at step 3, and for each subgroup of step 3, each of BaaiL through Baa 5 D were coupled to one group within the subgroup, resulting in 100 groups in 10 subgroups and 100 couplings.
• step 3 For each subgroup of step 3, the five Baa x L members and the five Baa x D members were separately pooled in step 4, resulting in 20 subgroups, with each subgroup containing five different sequences differing by the Baa x member.
• step 4 Each of the 20 subgroups of step 4 were then in step 5 divided into 10 groups (with only one shown for illustration purposes in Fig. 8), and for each subgroup, each of Aaa ⁇ through Aaa 5 D were coupled to one group within the subgroup, resulting in 200 groups in 20 subgroups and 200 couplings.
• step 5 For each subgroup of step 5, the five Aaa x L members and the five Aaa x D members were separately pooled in step 6, resulting in 40 subgroups, with each subgroup containing twenty-five different sequences differing by the Baa x and Aaa x member.
• step 7 each of the 40 subgroups of step 6 were divided into five groups, and each of R, through R 5 were coupled to one group within the subgroup, resulting in 200 groups in 40 subgroups, with each group containing 25 different sequences differing by the Baa x and Aaa x member.
• Peptides were synthesized using Fmoc chemistry, with side chain functionalities protected using acid labile groups.
• the SH group of the Cys residue was protected by a S'Bu OSPG cleavable in presence of both base and acid labile groups using tributylphosphine as the reducing agent.
• the peptide chain was assembled on the solid phase using 1-(1 H-benzotriazole-1-yl)-1 ,1 ,3,3,-tetra- methyluronium tetrafluoroborate (TBTU) as a coupling agent.
• TBTU 1-(1 H-benzotriazole-1-yl)-1 ,1 ,3,3,-tetra- methyluronium tetrafluoroborate
• the SH group was then selectively unprotected and rhenium metal ion complexed using the rhenium transfer agent Re(0)CI 3 (PPh 3 ) 2 in the presence of 1 ,8-D ⁇ azab ⁇ cyclo[5,4,0]undec-7-ene (DBU) as base.
• DBU rhenium transfer agent
• the metal-peptide complex was formed with the peptide chain still tethered to the solid support.
• the metallopeptide was then liberated from the solid support by treatment with TFA.
• This solid phase approach to metal ion complexation is fully compatible with split synthesis methodologies employed in combinatorial libraries.
• the synthesis process was performed using commercial automated synthesizers. Multiple manual synthesizers (such as those commercially available from SynPep Corporation, Dublin, CA) allow parallel synthesis of ten peptides simultaneously.
• Quality control protocols were employed as required, and include HPLC, mass spectral analysis, and ammo acid analysis on each individual pool of 25 compounds. The presence of each of pool constituent is established by molecular ion mass spectral analysis. Negative ion mode electron spray (ES) and matrix-assisted laser desorption (MALDI) techniques were employed.
• ES electrospray
• MALDI matrix-assisted laser desorption
• Rhenium thus acts as an internal mass spectral reference for these metallopeptides.
• a spectral analysis of one such pool of 25 compounds synthesized by the methods of this claim is shown at Fig. 9. Five sets of two metallopeptides in this pool have similar masses due to the presence of the same am o acids assembled in different sequences. The relative intensities of the peaks is due to differential lonization of individual compounds in the pool and does not reflect the relative amounts in the mixture.
• Metallopeptide library pools are screened for MC4-R receptor and MC1-R receptor binding activity in high throughput screening assays.
• the MC receptor-b dmg assay uses membrane preparations from B16-F1 or B16-F10 melanoma cells as the source of MC receptor.
• Cell membranes prepared from MC4-R-express ⁇ ng 293 cells and negative control, untransfected 293 cells, are substituted for B16-F1 or B16-F10 melanoma cell membranes in MC4-R specific binding assays.
• the MC receptor-b dmg assays use the Mil pore Multi-Screen System and are performed in 96-well Millipore filter plates (Durapore, 0.45 mm porosity) pre-blocked with 0.5% bovine serum albumin in phosphate buffered saline. Cell membrane preparations (12.5 ⁇ g/well) are incubated with 0.4 nM 125 I-NDP-MSH in HEPES Buffer containing 0.2% bovine serum albumin. Non-specific binding is determined by addition of l O ⁇ M ⁇ -MSH or 10 "7 M NDP-MSH. Metallopeptides to be tested are added to reaction wells at a final concentration of 1 mM.
• the binding reaction is rapidly terminated by filtration to capture the membranes. Filters are washed 3 times with ice-cold PBS and air-dried. Individual filters are then punched from the plates and distributed into gamma counter tubes. Radioactivity associated with the membranes is determined in a Packard Cobra gamma counter. Specific binding is determined as the radioactivity in wells containing 125 I-NDP-MSH alone minus the radioactivity in wells containing lO ⁇ M ⁇ -MSH. Test compounds are screened in duplicate wells and are considered to be active where 1 ⁇ M concentrations inhibit >50% of the specific binding. Standard curves of unlabeled NDP-MSH will be included on each plate as an internal assay control.
• cAMP kit R&D Systems, DE0350, low pH
• 293 cells stably transfected with hMC-4 receptor, or B16-F1 melanoma cells are grown to confluence in 96-well dishes. Ceils are washed and fresh RPM I containing 0.2 mM isobutylmethylxanthine (cAMP phosphodiesterase) and varying concentrations of metallopeptides, or ⁇ -MSH as a positive control, are added, and the cells are incubated for 1 hour at 37°C.
• cAMP phosphodiesterase isobutylmethylxanthine
• Example 4 DECONVOLUTION OF MELANOCORTIN RECEPTOR-SPECIFIC LIBRARY Deconvolution of a positive pool is done by iterative re-synthesis and screening deconvolution approaches.
• the individual 25 constituents are synthesized separately, or alternatively in 5 smaller pools of 5 compounds each, with each pool screened in receptor binding assays. The latter approach is preferred where there is a high hit frequency in the preliminary screen.
• the compounds in pools with the best results are individually synthesized and screened.
• an alternative method of mass spectral deconvolution of metallopeptide libraries is employed.
• the method is based on the internal signature of rhenium-complexed peptides (two isotopic peaks in 1 :2 ratios differing by 2 mass units), which generally permits metallopeptide identification even in mixed solutions.
• a positive pool is incubated with receptor-bearing cells, the excess unbound compounds washed away under controlled conditions, and the cells treated with a solvent to disrupt metallopeptide binding and extract the metallopeptide in the solvent.
• Example 2 A synthesis procedure similar to that described in Example 1 was used in making this library.
• a NovaSyn TGR resin for making peptide amides (substitution 0.2 mM/gm) was used.
• Fmoc synthetic strategy was employed using the following protected amino acids: Fmoc-Trp(Boc), Fmoc-Cys(S'Bu), Fmoc-Xxx, and Fmoc-His(Trityl).
• the Xaa amino acids were Trp, HomoPhe, 2'-Naphthylalanine, and Phenylglycine.
• the peptide resin Cys(S l Bu)-Trp-NH 2 was split into four equal pools and one of the Xaa amino acids was coupled to one individual pool. After completion of the coupling reaction, the four resin pools were mixed again. The synthesis proceeded with the coupling of His followed by acetylation of the N-terminus. After the complete assembly of the peptide chain Ac-His(Trt)-Xaa- Cys(S l Bu)-Trp(Boc)-NH 2 , the S'Bu group was removed by treatment with DMF/tributyiphosphine and rhenium-oxo metal ion was complexed as generally described above.
• the fully protected metallopeptide was deblocked and liberated from the solid support by treatment with a cleavage cocktail (95:5 mixture of trifluoroacetic acid - triisopropylsilane) for three hours.
• the metallopeptide library was recovered by precipitation using cold ether. The resulting pellet was washed twice and 0.5 ml of 95% acetic acid was added. After one-half hour 5 ml of water was added and the solution was freeze-dried yielding the desired library in solid form.
• Mass spectrometric analysis of the library pool confirmed the correct masses for all four members of the library:
• High potency metallopeptides are also provided with N-termmal modifications
• Systematic N- terminal modifications are made based upon the limited data available in the literature related to receptor-bmdmg affinities of peptide analogs for various MC receptor types
• these studies indicate that the H ⁇ s6 residue may be a critical factor in determining receptor selectivity for MC1-R (peripheral) versus MC4-R (brain)
• Three-dimensional molecular models of the human meianocortin receptor have been developed based upon the electron cryo-microscopic structure of bactenorhodopsin and the electron density footprint of bovine rhodopsm By modeling known potent agonists into the proposed binding sites, specific ligand-receptor interactions have been identified.
• R is a pair consisting of a hydrophobic side chain and hydrophilc side chain with hydrogen bonding potential which is selected from the following groups
• n is from 2 to 9 and X and/or Y are selected from H, OH, CI, Br, I, NH 2 , OCH 3 , N0 2 and similar groups.
• Example 8 SKIN DARKENING IN ANOLIS CAROLINENSIS PT-1145 complexed with rhenium (0.65 mg taken in a 50 mL vehicle) was injected intraperitoneally in a lizard (Anolis carolinensis) that was pre-conditioned for a skin darkening experiment.
• the pre-conditioning involved leaving the lizards in a well-lit white background for 24 hours.
• the skin coat color turned from bright green to dark brown to black.
• the skin coat color remained dark during the five-hour observation period.
• Lizards injected with the vehicle alone PBS buffer containing 1 % each of DMF and beta-cyclodextran

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Endocrinology (AREA)
• Toxicology (AREA)
• Gastroenterology & Hepatology (AREA)
• Zoology (AREA)
• Reproductive Health (AREA)
• Obesity (AREA)
• Gynecology & Obstetrics (AREA)
• Child & Adolescent Psychology (AREA)
• Analytical Chemistry (AREA)
• Dermatology (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Applications Claiming Priority (3)

Publications (2)

Family

ID=22528350

Family Applications (1)

Country Status (5)

Families Citing this family (14)

Citations (2)

Family Cites Families (5)

• 2000
  • 2000-06-15 WO PCT/US2000/016396 patent/WO2001013112A1/en active Search and Examination
  • 2000-06-15 AU AU58742/00A patent/AU5874200A/en not_active Abandoned
  • 2000-06-15 JP JP2001517163A patent/JP2004519410A/ja active Pending
  • 2000-06-15 EP EP00944681A patent/EP1208377A4/de not_active Withdrawn
  • 2000-06-15 CA CA002379647A patent/CA2379647A1/en not_active Abandoned

Patent Citations (2)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events